Experiences with generics

International Journal of Risk and Safety in Medicine

Volumn 15, Issue 1-2, 2002, Pages 101-109

  De Joncheere, Kees ^a   Rietveld, Ad H ^a   Huttin, Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

CANADA; DENMARK; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PREFERENCE; GERMANY; HUMAN; NETHERLANDS; PATIENT EDUCATION; PRESCRIPTION; REVIEW; UNITED KINGDOM; UNITED STATES;

EID: 0036969480     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. A.H. Anis, Substitution laws, insurance coverage, and generic drug use, Medical Care 32(3), 240-256.
2. R.E. Caves, M.D. Whinston and M.A. Hurwitz, Patent expiration, entry and competition in the US pharmaceutical market, Brookings papers on economic activity, 1991.
3. Council of Ministers of the European Commission, Development: Communicable diseases and poverty, 2304th Council meeting, Brussels, 10 November 2000.
4. European Generic Manufacturers Association EGA, http://www.egagenerics.com/facts_figures/facts_figures.htm, accessed June 2001.
5. European Commission, Commission Communication on the Single market in pharmaceuticals, COM (98) 588 final, Brussel, November 5th, 1998.
6. European Commission, Pharmaceutical Legislation 2001 Review, http://dg3.eudra.org/F2/review/index.htm, accessed April 2002.
7. H. Grabowski and J. Vernon, Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act, Journal of Law and Economics (October 1992).
8. H.G. Grabowski and J.M. Vernon, Longer patents for lower imitation barriers: the 1984 Drug Act, American Economic Association Papers and Proceedings, Vol. 76, May 1986.
9. W. Haddad, A generic manufacturer's perspective, Paper delivered to the WHO/WTO Workshop on Differential Pricing and Financing of Essential Drugs, Høsbjør, 8-11 April 2001.
10. C. Huttin, La regulation des prix du medicaments en Allemagne, document interne, Commission Europeenne D6 III, 1992.
11. J. Jones, Government orders inquiry as prices of generic drugs soar, BMJ 319 (1999), 1151.
12. LSE Survey on Pharmaceutical Pricing and Reimbursement Structures in the European Union and Worldwide, http://pharmacos.eudra.org/F3/g10/p6.htm.
13. Medical Letter 41 (1999), 1053; 47-48 Generic drugs.
14. M. Mrazek and E. Mossialos, Increasing demand while decreasing costs of generic medicines, Lancet 356 (2000), 1784-1785.
15. National Institute of Health Care Management, USA, A Primer: Generic drugs, Patents and the Pharmaceutical Marketplace, http://www.nihcm.org/GenericsPrimer.pdf.accessed June 30, 2002.
16. D. Reiffen and M. Ward, Generic drug industry dynamics, Federal Trade Commission Bureau of Economics (2002), http://www.ftc.gov/be/workpapers/industrydynamicsreiffenwp.pdf, accessed 6 May 2002.
17. S.W. Schondelmeyer and J. Thomas 3rd, Trends in retail prescription expenditures, Health Aff. (Millwood) F 9(3) (1990), 131-145.
18. Council Directive 87/21, O.J. 1987, L15/36.
19. Scrip Magazine, 13-19 February 2000, Persistence pays off.
20. Third Round Table "Completing the Single Market in Medicines" Round Table organised by Martin Bangemann, European Commission, December 7th, 1998, Proceedings published by EFPIA in collaboration with IMS Health.
21. USA Congressional Budget office, How increased competition from generic drugs has prices and returns in the pharmaceutical industry, July 1998, http://www.cbo.gov/showdoc.cfm?index=655&sequence=0&from=5, accessed 1 March 2002.
22. Washington Post, 23 April 2002, Drug firm, FTC settle patent dispute, http://www.washingtonpost.com/wp-dyn/articles/A37639-2002Apr23.
23. World Health Organisation, Marketing authorisations of pharmaceutical products with special reference to generic (multisource) products, WHO/DMP/RGS/98.5, 1998.